Other Species / Isoforms
  SH2D4A (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
Y10-p
KQILSEMyIDPDLLA
0 1
SH2D4A (human) KQILSEMyIDPDLLA Y10-p
SH2D4A (mouse) RQILSDMFIDPDLLA F10
SH2D4A (rat) RQILSEMFIDPDLLA F10
K49-ub
REAAMERkEsLPVkP
0 1
SH2D4A (human) REAAMERkEsLPVkP K49-ub
SH2D4A (mouse) REAAMERKESLPVKS K49
SH2D4A (rat) REAAMERKESLPVKS K49
S51-p
AAMERkEsLPVkPRP
0 3
SH2D4A (human) AAMERkEsLPVkPRP S51-p
SH2D4A (mouse) AAMERKESLPVKSRP S51
SH2D4A (rat) AAMERKESLPVKSRP S51
K55-ub
RkEsLPVkPRPKKEN
0 1
SH2D4A (human) RkEsLPVkPRPKKEN K55-ub
SH2D4A (mouse) RKESLPVKSRPKKEN K55
SH2D4A (rat) RKESLPVKSRPKKEN K55
K69-ac
NGKSVHWkLGADKEV
0 1
SH2D4A (human) NGKSVHWkLGADKEV K69-ac
SH2D4A (mouse) NGKSVHWKLGADKQV K69
SH2D4A (rat) NGKSVHWKLGADKQV K69
K69-ub
NGKSVHWkLGADKEV
0 1
SH2D4A (human) NGKSVHWkLGADKEV K69-ub
SH2D4A (mouse) NGKSVHWKLGADKQV K69
SH2D4A (rat) NGKSVHWKLGADKQV K69
K105-ub
IAERARLkAEQEAEE
0 1
SH2D4A (human) IAERARLkAEQEAEE K105-ub
SH2D4A (mouse) LAEREHLRAAKDSEL R105
SH2D4A (rat) LAEREHLRAAKDAEL R105
K105-sm
IAERARLkAEQEAEE
0 1
SH2D4A (human) IAERARLkAEQEAEE K105-sm
SH2D4A (mouse) LAEREHLRAAKDSEL R105
SH2D4A (rat) LAEREHLRAAKDAEL R105
K115-ub
QEAEEPRkTHsEEFT
0 2
SH2D4A (human) QEAEEPRkTHsEEFT K115-ub
SH2D4A (mouse) AKDSELRKTQsLELA K114
SH2D4A (rat) AKDAELRKAQSLQFT K114
S118-p
EEPRkTHsEEFTNsL
0 2
SH2D4A (human) EEPRkTHsEEFTNsL S118-p
SH2D4A (mouse) SELRKTQsLELANSL S117-p
SH2D4A (rat) AELRKAQSLQFTNSL S117
S124-p
HsEEFTNsLkTksQy
0 8
SH2D4A (human) HsEEFTNsLkTksQy S124-p
SH2D4A (mouse) QsLELANSLKIKSQN S123
SH2D4A (rat) QSLQFTNSLKVKSLN S123
K126-ub
EEFTNsLkTksQyHD
0 2
SH2D4A (human) EEFTNsLkTksQyHD K126-ub
SH2D4A (mouse) LELANSLKIKSQNCD K125
SH2D4A (rat) LQFTNSLKVKSLNCD K125
K128-ub
FTNsLkTksQyHDLQ
0 1
SH2D4A (human) FTNsLkTksQyHDLQ K128-ub
SH2D4A (mouse) LANSLKIKSQNCDLQ K127
SH2D4A (rat) FTNSLKVKSLNCDLQ K127
K128-m1
FTNsLkTksQyHDLQ
0 1
SH2D4A (human) FTNsLkTksQyHDLQ K128-m1
SH2D4A (mouse) LANSLKIKSQNCDLQ K127
SH2D4A (rat) FTNSLKVKSLNCDLQ K127
S129-p
TNsLkTksQyHDLQA
0 2
SH2D4A (human) TNsLkTksQyHDLQA S129-p
SH2D4A (mouse) ANSLKIKSQNCDLQA S128
SH2D4A (rat) TNSLKVKSLNCDLQA S128
Y131-p
sLkTksQyHDLQAPD
Upstream
0 70
Treatment
  • gefitinib
  • PD173074
  • Su11274
SH2D4A (human) sLkTksQyHDLQAPD Y131-p
SH2D4A (mouse) SLKIKSQNCDLQAMK N130
SH2D4A (rat) SLKVKSLNCDLQAVK N130
K143-ub
APDNQQTkDIWKKVA
0 1
SH2D4A (human) APDNQQTkDIWKKVA K143-ub
SH2D4A (mouse) AMKKTEPQNVTRKAA Q142
SH2D4A (rat) AVKKTEPQNVTRKAA Q142
K152-ub
IWKKVAEkEELEQGS
0 1
SH2D4A (human) IWKKVAEkEELEQGS K152-ub
SH2D4A (mouse) VTRKAASEEASGQGP E151
SH2D4A (rat) VTRKAAAEEATDQGP E151
T164
QGSRPAPTLEEEkIR
0 1
SH2D4A (human) QGSRPAPTLEEEkIR T164
SH2D4A (mouse) QGPRAIPtRKDDKAQ T163-p
SH2D4A (rat) QGPRAIPTKKDDKAQ T163
K169-ub
APTLEEEkIRSLSSS
0 1
SH2D4A (human) APTLEEEkIRSLSSS K169-ub
SH2D4A (mouse) IPtRKDDKAQTKPVK K168
SH2D4A (rat) IPTKKDDKAQTKDLT K168
S177-p
IRSLSSSsRNIQQML
0 1
SH2D4A (human) IRSLSSSsRNIQQML S177-p
SH2D4A (mouse) gap -
SH2D4A (rat) gap -
S187-p
IQQMLADsINRMKAY
0 1
SH2D4A (human) IQQMLADsINRMKAY S187-p
SH2D4A (mouse) gap -
SH2D4A (rat) gap -
K199-ub
KAYAFHQkKESMKKK
0 1
SH2D4A (human) KAYAFHQkKESMKKK K199-ub
SH2D4A (mouse) gap -
SH2D4A (rat) gap -
S235-p
EDSEWQAsLRKSkAA
Upstream
0 4
Treatment
  • ischemia
SH2D4A (human) EDSEWQAsLRKSkAA S235-p
SH2D4A (mouse) EDSEWQAsLRKSKAA S206-p
SH2D4A (rat) EDSEWQASLRKSKAA S207
K240-m1
QAsLRKSkAADEKRR
0 1
SH2D4A (human) QAsLRKSkAADEKRR K240-m1
SH2D4A (mouse) QAsLRKSKAADEKRR K211
SH2D4A (rat) QASLRKSKAADEKRR K212
S261-p
REDYKRLsLGAQKGR
Upstream
0 16
Kinase, in vitro:
  • AurB (human)
Treatment
  • AZD1152
  • BI2536
  • MLN8054
  • nocodazole
  • ZM447439
SH2D4A (human) REDYKRLsLGAQKGR S261-p
SH2D4A (mouse) REDYKRLSQRGRSGD S232
SH2D4A (rat) REDYKRLSQrGRSGD S233
K266
RLsLGAQKGRGGERL
0 1
SH2D4A (human) RLsLGAQKGRGGERL K266
SH2D4A (mouse) DYKRLSQRGRSGDGL R234
SH2D4A (rat) DYKRLSQrGRSGDGL R235-m1
S275-p
RGGERLQsPLRVPQK
0 4
SH2D4A (human) RGGERLQsPLRVPQK S275-p
SH2D4A (mouse) RSGDGLQNPLTGPQK N243
SH2D4A (rat) RSGDGLQNPLTGPQK N244
K303-ac
NSGAYPQkPLRNQGV
0 1
SH2D4A (human) NSGAYPQkPLRNQGV K303-ac
SH2D4A (mouse) QPLGIPPKSLGNQGV K271
SH2D4A (rat) QPLGSPPKSLGNQGV K272
T313-p
RNQGVVRtLsssAQE
0 4
SH2D4A (human) RNQGVVRtLsssAQE T313-p
SH2D4A (mouse) GNQGVIRTEISSAQM T281
SH2D4A (rat) GNQGVIRTKTSSTQE T282
S315-p
QGVVRtLsssAQEDI
Upstream
0 82
Treatment
  • EGF
  • ischemia
  • metastatic potential
  • nocodazole
  • rapamycin
  • SB202190
  • U0126
SH2D4A (human) QGVVRtLsssAQEDI S315-p
SH2D4A (mouse) QGVIRTEISSAQMDT I283
SH2D4A (rat) QGVIRTKTSSTQEDI T284
S316-p
GVVRtLsssAQEDII
0 9
SH2D4A (human) GVVRtLsssAQEDII S316-p
SH2D4A (mouse) GVIRTEISSAQMDTI S284
SH2D4A (rat) GVIRTKTSSTQEDII S285
S317-p
VVRtLsssAQEDIIR
0 8
SH2D4A (human) VVRtLsssAQEDIIR S317-p
SH2D4A (mouse) VIRTEISSAQMDTIR S285
SH2D4A (rat) VIRTKTSSTQEDIIR S286
K327-ub
EDIIRWFkEEQLPLR
0 1
SH2D4A (human) EDIIRWFkEEQLPLR K327-ub
SH2D4A (mouse) MDTIRWFKEEQLPFR K295
SH2D4A (rat) EDIIRWFKEEQLPFR K296
K327-sm
EDIIRWFkEEQLPLR
0 1
SH2D4A (human) EDIIRWFkEEQLPLR K327-sm
SH2D4A (mouse) MDTIRWFKEEQLPFR K295
SH2D4A (rat) EDIIRWFKEEQLPFR K296
Y438
LGKELLLYPCGQQDQ
0 1
SH2D4A (human) LGKELLLYPCGQQDQ Y438
SH2D4A (mouse) LGKELLLyPCGQQDK Y405-p
SH2D4A (rat) LGKELLLFPCGQQDK F406